OCGN Stock Price, Ocugen Inc Quote, Chart

Market Summary

USD1.90-0.08

Market Closed

-4.04%

OCGN Stock Price

View Fullscreen

OCGN RSI Chart

OCGN Valuation

Market Cap

488.9M

Price/Earnings (Trailing)

-8.48

Price/Sales (Trailing)

74

EV/EBITDA

-7.36

Price/Free Cashflow

-7.45

OCGN Price/Sales (Trailing)

OCGN Profitability

EBT Margin

-954.71%

Return on Equity

-190.52%

Return on Assets

-111.31%

Free Cashflow Yield

-13.42%

OCGN Fundamentals

OCGN Revenue

Revenue (TTM)

6.6M

Rev. Growth (Yr)

60.3%

Rev. Growth (Qtr)

-61.91%

OCGN Earnings

Earnings (TTM)

-57.7M

Earnings Growth (Yr)

31.32%

Earnings Growth (Qtr)

-8.48%

Breaking Down OCGN Revenue

Last 7 days

19.5%

Last 30 days

31.9%

Last 90 days

100%

Trailing 12 Months

188.7%

How does OCGN drawdown profile look like?

OCGN Financial Health

Current Ratio

1.87

Debt/Equity

0.05

Debt/Cashflow

-35.49

OCGN Investor Care

Shares Dilution (1Y)

13.65%

Diluted EPS (TTM)

-0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.6M	0	0	0
2023	2.4M	2.3M	5.5M	6.0M
2022	654.3K	1.3M	1.9M	2.5M
2020	0	0	0	43.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ocugen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 03, 2024	musunuri shankar	sold (taxes)	-117,673	0.653	-180,204	chief executive officer
Jan 03, 2024	upadhyay arun	sold (taxes)	-27,186	0.653	-41,633	see remarks
Sep 16, 2023	upadhyay arun	sold (taxes)	-345	0.41	-842	see remarks
Jun 16, 2023	upadhyay arun	sold (taxes)	-467	0.51	-917	chief scientific officer
Jun 14, 2023	zhang junge	bought	99,998	0.4993	200,278	-
Feb 16, 2023	musunuri shankar	sold	-108,000	1.08	-100,000	chief executive officer
Feb 16, 2023	musunuri shankar	acquired	33,000	0.33	100,000	chief executive officer
Jan 17, 2023	musunuri shankar	acquired	51,000	0.51	100,000	chief executive officer
Jan 17, 2023	musunuri shankar	sold	-128,000	1.28	-100,000	chief executive officer
Jan 03, 2023	musunuri shankar	sold (taxes)	-47,346	1.25	-37,877	chief executive officer

Which funds bought or sold OCGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	VIMA LLC	added	100	412	622	-%
May 16, 2024	JANE STREET GROUP, LLC	added	1,418	320,922	328,505	-%
May 16, 2024	Tidal Investments LLC	new	-	108,255	108,255	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	368	2,921,930	3,158,240	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	551	551	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	4,276,500	4,276,500	-%
May 15, 2024	Royal Bank of Canada	added	282	13,000	14,000	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	552	1,592,200	1,682,650	-%
May 15, 2024	Cetera Advisor Networks LLC	sold off	-100	-11,673	-	-%
May 15, 2024	LUMINUS MANAGEMENT LLC	sold off	-100	-935,285	-	-%

Are Funds Buying or Selling OCGN?

Are funds buying OCGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCGN

No. of Funds

Unveiling Ocugen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.69%	12,039,918	SC 13G/A
Jan 22, 2024	state street corp	0.33%	835,826	SC 13G/A
Jul 07, 2023	blackrock inc.	1.5%	3,907,414	SC 13G/A
Feb 10, 2023	state street corp	13.76%	30,121,024	SC 13G/A
Feb 09, 2023	vanguard group inc	5.42%	11,859,143	SC 13G/A
Feb 01, 2023	blackrock inc.	6.9%	15,061,361	SC 13G/A
Apr 11, 2022	state street corp	13.57%	29,153,704	SC 13G/A
Feb 11, 2022	state street corp	7.04%	14,017,619	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	12,931,131	SC 13G
Feb 10, 2021	vanguard group inc	5.60%	9,074,993	SC 13G

Recent SEC filings of Ocugen Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	PRE 14A	PRE 14A
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 10, 2024	8-A12G	8-A12G
May 10, 2024	8-K	Current Report
May 01, 2024	EFFECT	EFFECT
Apr 29, 2024	10-K/A	Annual Report
Apr 29, 2024	8-K	Current Report
Apr 18, 2024	S-3	S-3
Apr 18, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Ocugen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ocugen Inc News

Latest updates

Ocugen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2020Q4	2020Q3	2020Q2
Revenue	-28.0%	1,014,000	1,409,000	3,699,000	485,000	443,000	879,000	466,000	643,000	500,000	347,667	195,333	43,000
Operating Expenses	2.3%	13,230,000	12,934,000	16,130,000	24,025,000	18,478,000	24,234,000	25,576,000	22,219,000	19,530,000	3,808,000	10,182,000	3,409,000
S&GA Expenses	-100.0%	-	5,155,000	9,082,000	9,451,000	8,306,000	7,007,000	7,639,000	10,617,000	10,137,000	2,214,000	1,704,000	1,779,000
EBITDA Margin	8.6%	-9.55	-10.45	-12.48	-30.22	-28.26	-27.61	-30.94	-45.88	-88.75	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	166,000	292,000	248,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-21,939,000	-21,922,000	-	-	-	-10,474,000	-
EBT Margin	8.6%	-9.55	-10.45	-12.58	-30.47	-28.49	-27.83	-31.13	-46.16	-89.29	-	-	-
Net Income	-8.5%	-11,900,000	-10,970,000	-11,717,000	-23,065,000	-17,326,000	-22,394,000	-23,913,000	-21,482,000	-19,015,000	-3,790,000	-10,474,000	-3,614,000
Net Income Margin	16.5%	-8.73	-10.45	-13.53	-38.14	-35.01	-34.89	-42.09	-52.02	-107	-	-	-
Free Cashflow	7.7%	-12,947,000	-14,024,000	-17,071,000	-21,583,000	-19,852,000	-18,938,000	-15,146,000	-15,163,000	-15,289,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-19.8%	52.00	65.00	75.00	89.00	96.00	109	116	130	142	106	116	124	54.00	27.00	21.00	24.00	12.00	17.00	24.00	4.00	15.00
Current Assets	-30.2%	30.00	43.00	57.00	73.00	84.00	98.00	107	123	138	103	113	122	51.00	26.00	20.00	23.00	11.00	16.00	23.00	3.00	8.00
Cash Equivalents	-33.2%	26.00	39.00	53.00	71.00	68.00	78.00	102	115	130	95.00	107	116	45.00	24.00	19.00	15.00	3.00	8.00	15.00	1.00	0.00
Net PPE	2.1%	18.00	17.00	14.00	12.00	8.00	6.00	5.00	3.00	2.00	1.00	-	-	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-10.2%	22.00	24.00	25.00	30.00	31.00	35.00	31.00	24.00	16.00	10.00	9.00	8.00	7.00	6.00	6.00	9.00	5.00	6.00	37.00	10.00	20.00
Current Liabilities	-6.1%	16.00	17.00	20.00	24.00	27.00	29.00	25.00	18.00	13.00	7.00	6.00	5.00	4.00	4.00	4.00	7.00	3.00	5.00	35.00	9.00	2.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	1.00	4.00	-	-	-	4.00	1.00
Long Term Debt	-45.2%	2.00	3.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-
LT Debt, Current	-	1.00	-	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	3.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-
Shareholder's Equity	-25.4%	30.00	41.00	50.00	59.00	65.00	74.00	86.00	106	126	91.00	107	116	46.00	22.00	14.00	15.00	7.00	11.00	-	-	-
Retained Earnings	-4.2%	-298	-286	-275	-263	-240	-223	-200	-176	-155	-131	-117	-106	-80.38	-73.30	-69.50	-59.04	-55.40	-51.48	-63.86	-41.09	-226
Additional Paid-In Capital	0.5%	326	324	322	320	303	295	284	281	279	226	222	221	125	93.00	82.00	72.00	62.00	62.00	51.00	35.00	220
Shares Outstanding	0.3%	257	257	256	256	226	222	217	216	206	199	194	196	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	137	-	-	-	483	-	-	-	1,600	-	-	-	29.00	-	-	-	18.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	6.3%	-10,595	-11,302	-13,706	-18,806	-18,240	-16,914	-14,302	-13,797	-15,066	-12,804	-8,053	-21,801	-5,283	-4,283	-2,653	-3,087	-4,686	-8,743	-2,118	-3,363	-2,667
Share Based Compensation	-100.0%	-	1,722	2,174	2,632	2,689	2,668	2,495	2,079	3,299	2,683	1,347	2,095	833	163	126	149	222	164	193	112	415
Cashflow From Investing	13.6%	-2,352	-2,722	-3,365	5,723	3,441	-15,295	-83.00	-1,366	-223	-192	-350	-1,013	-261	-251	-22.00	19.00	-53.00	-20.87	-2,204	-121	-10.58
Cashflow From Financing	-1006.2%	-145	16.00	-35.00	15,404	5,496	8,175	962	236	50,102	605	110	93,664	26,297	9,467	6,813	14,843	488	907	18,945	3,855	1,359

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OCGN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 1,014	$ 443
Operating expenses
Research and development	6,826	10,172
General and administrative	6,404	8,306
Total operating expenses	13,230	18,478
Loss from operations	(12,216)	(18,035)
Other income (expense), net	292	709
Net loss	(11,924)	(17,326)
Other comprehensive income (loss)
Foreign currency translation adjustment	5	(1)
Comprehensive loss	$ (11,919)	$ (17,327)
Shares used in calculating net loss per common share - diluted (in shares)	257,232,636	225,523,627
Shares used in calculating net loss per common share - basic (in shares)	257,232,636	225,523,627
Net loss per share of common stock - basic (in USD per share)	$ (0.05)	$ (0.08)
Net loss per share of common stock - diluted (in USD per share)	$ (0.05)	$ (0.08)
Total revenue	$ 1,014	$ 443
Collaborative Arrangements
Total revenue	1,014	443
Operating expenses
Research and development	100	1,500
Other comprehensive income (loss)
Total revenue	$ 1,014	$ 443

OCGN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 26,375	$ 39,462
Prepaid expenses and other current assets	3,623	3,509
Total current assets	29,998	42,971
Property and equipment, net	17,654	17,290
Other assets	4,142	4,286
Total assets	51,794	64,547
Current liabilities
Accounts payable	1,731	3,172
Accrued expenses and other current liabilities	12,434	13,343
Operating lease obligations	589	574
Current portion of long term debt	1,296	0
Total current liabilities	16,050	17,089
Non-current liabilities
Operating lease obligations, less current portion	3,414	3,567
Long term debt, net	1,533	2,800
Other non-current liabilities	536	527
Total non-current liabilities	5,483	6,894
Total liabilities	21,533	23,983
Commitments and contingencies
Stockholders' equity
Common stock; $0.01 par value; 295,000,000 shares authorized, 257,446,764 and 256,688,304 shares issued, and 257,325,264 and 256,566,804 shares outstanding at March 31, 2024 and December 31, 2023, respectively	2,575	2,567
Treasury stock, at cost, 121,500 shares at March 31, 2024 and December 31, 2023	(48)	(48)
Additional paid-in capital	325,799	324,191
Accumulated other comprehensive income	25	20
Accumulated deficit	(298,091)	(286,167)
Total stockholders' equity	30,261	40,564
Total liabilities and stockholders' equity	51,794	64,547
Series A Preferred Stock
Stockholders' equity
Preferred stock issued	0	0
Series B Preferred Stock
Stockholders' equity
Preferred stock issued	$ 1	$ 1

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

CEO	Dr. Shankar Musunuri M.B.A., MBA, Ph.D.
WEBSITE	ocugen.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Ocugen Inc Frequently Asked Questions

What is the ticker symbol for Ocugen Inc? What does OCGN stand for in stocks?

OCGN is the stock ticker symbol of Ocugen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocugen Inc (OCGN)?

As of Fri May 17 2024, market cap of Ocugen Inc is 488.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers. The fair value of Ocugen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocugen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocugen Inc a good stock to buy?

The fair value guage provides a quick view whether OCGN is over valued or under valued. Whether Ocugen Inc is cheap or expensive depends on the assumptions which impact Ocugen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCGN.

What is Ocugen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OCGN's PE ratio (Price to Earnings) is -8.48 and Price to Sales (PS) ratio is 74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCGN PE ratio will change depending on the future growth rate expectations of investors.